Shaken By Recall Of Claris' IV Products, Pfizer Puts Brakes On Vials Too; Vows To Ensure Patient Safety
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Faced with an undesirable ordeal of a nationwide recall of metronidazole, ciprofloxacin and ondansetron in the United States - the three intravenous hospital products sourced from its Indian partner Claris Lifesciences - the world's largest pharma company Pfizer has decided to stop distribution of the vial forms of the drug "out of abundance of caution.
You may also be interested in...
Pfizer Goes Big On Generic Injectables With Acquisition Of 15 Products From India’s Claris
AHMEDABAD, India - Two months after Pfizer signed a comprehensive in-licensing agreement for more than 50 oral and injectable products with Aurobindo Pharma, the U.S. company has entered into another deal, with India's Claris Lifesciences, to commercialize 15 products covering a broad range of therapeutic areas including anti-infectives and pain drugs
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).